Researchers from the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, joined oncology professionals around the world for the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO21), held online from June 4 through June 8.
This year’s event celebrated the many advances in cancer research, treatment and patient care, while also focusing on health equity and identifying ways to ensure that all patients have access to and benefit from the latest cancer advances and high-quality cancer care.
Nearly 20 abstracts from our team of physician scientists and immunologists were selected for presentation or publication at ASCO21. From a first-in-human immunotherapy trial for cancers associated with human papillomavirus, to a study of the benefits of yoga and cognitive behavioral therapy for cancer survivors suffering from impaired sleep, the abstracts reflect our commitment to improving patient outcomes and quality of life across the continuum of cancer care.
Highlights included abstracts selected for oral presentation and discussion at sessions for Developmental Therapeutics - Immunotherapy, Gastrointestinal Cancer, Head and Neck Cancer, Lung Cancer, and Symptoms and Survivorship.
Additionally, Rachel Sanborn, M.D., medical director, Providence Thoracic Oncology Program and Phase I Clinical Trials Program, was invited to offer her expert insight on the ASCO21 highlights for lung cancer.
View our list of ASCO21 abstracts and links to further reading below:
Oral Abstract Session
Developmental Therapeutics – Immunotherapy
Abstract 2502 - First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers. A Lo…R Leidner et al.
Gynecologic Cancer
Abstract 5508 - Pertuzumab plus trastuzumab in patients with uterine cancer with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry study. HM Ali-Ahmad…R Li et al.
Lung Cancer – Non-Small Cell Metastatic
Abstract 9006 - CHRYSALIS study: Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant non-small cell lung cancer and potential biomarkers for response. J Bauml…RE Sanborn et al.
Poster Discussion Session
Developmental Therapeutics – Immunotherapy
Abstract 2516 - A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. HA Burris III…M Taylor et al.
Gastrointestinal Cancer – Colorectal and Anal
Abstract 3508 - CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial. H Kennecke et al.
Head and Neck Cancer
Abstract 6010 - Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group. Rl Ferris…RB Bell et al.
Symptoms and Survivorship
Abstract 12017 - Effects of yoga, cognitive behavioral therapy, and a behavioral placebo on sleep: A nationwide multicenter phase III RCT in cancer survivors. P Lin…A Conlin et al.
Poster Session
Developmental Therapeutics – Immunotherapy
Abstract 2536 - Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101. A Jimeno…M Taylor et al.
Abstract 2578 - Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts. S Wong…RE Sanborn et al.
Abstract 2585 - A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. RE Sanborn et al.
Abstract TPS2657 - A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. E Garralda…RE Sanborn et al.
Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Abstract TPS3144 - A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors. A Patnaik…RE Sanborn et al.
Head and Neck Cancer
Abstract TPS6085 - Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer. M Taylor, R Leidner, RB Bell, BA Fox et al.
Abstract 6043 - Palbociclib in patients with head and neck cancer with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry study. E Pisick…R Leidner et al.
Abstract 4086 - Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. G Abou-Alfa…G Vaccaro et al.
Lung Cancer – Non-Small Cell Metastatic
Abstract 9100 - Interim results of viagenpumatucel-L plus nivolumab in previously treated patients with advanced non-small cell lung cancer in two treatment settings. R Cohen…RE Sanborn et al.
Publication
Developmental Therapeutics – Immunotherapy
Abstract e14535 - Unaltered IL-2 encapsulated in acoustically active lipid microspheres for systemic but targeted microdose delivery to tumor microenvironment. C Larsen…W Redmond et al.
Gastrointestinal Cancer – Colorectal and Anal
Abstract e15543 - Treatment dependent improvements in survival of stage 2/3 rectal cancer patients treated with trimodality therapy between 2006-2016, an NCDB analysis. H Kennecke et al.
Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia
Abstract e19513 - Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel in the nonuniversity setting. J Godwin et al.
All abstracts from ASCO21 are available online. You can also view the program, daily news and bonus content.
To learn more about Providence Cancer Institute, follow us on Twitter, Facebook, and Linkedin. Visit our website and explore our blog for the latest cancer news, articles and more.
